JP2009531281A5 - - Google Patents

Download PDF

Info

Publication number
JP2009531281A5
JP2009531281A5 JP2008552645A JP2008552645A JP2009531281A5 JP 2009531281 A5 JP2009531281 A5 JP 2009531281A5 JP 2008552645 A JP2008552645 A JP 2008552645A JP 2008552645 A JP2008552645 A JP 2008552645A JP 2009531281 A5 JP2009531281 A5 JP 2009531281A5
Authority
JP
Japan
Prior art keywords
inhibitor
tubulin polymerization
kit
compound
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008552645A
Other languages
English (en)
Other versions
JP2009531281A (ja
JP5315060B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2007/000101 external-priority patent/WO2007087684A1/en
Publication of JP2009531281A publication Critical patent/JP2009531281A/ja
Publication of JP2009531281A5 publication Critical patent/JP2009531281A5/ja
Application granted granted Critical
Publication of JP5315060B2 publication Critical patent/JP5315060B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (13)

  1. 請求項１記載の式(I)の化合物またはその医薬的に許容される塩を含む、チューブリン重合阻害剤。
  2. 請求項２記載の式(Ia)の化合物またはその医薬的に許容される塩を含む、チューブリン重合阻害剤。
  3. 請求項４記載の式(Ib)の化合物またはその医薬的に許容される塩を含む、チューブリン重合阻害剤。
  4. 請求項５記載の式(II)の化合物またはその医薬的に許容される塩を含む、チューブリン重合阻害剤。
  5. 固形腫瘍を治療するための、請求項１５〜１８のいずれか記載の阻害剤。
  6. 少なくとも一つの他の細胞毒性化合物を請求項１５記載の阻害剤とともに含む、チューブリン重合の阻害用キット。
  7. 少なくとも一つの他の細胞毒性化合物を請求項１６記載の阻害剤とともに含む、チューブリン重合の阻害用キット。
  8. 少なくとも一つの他の細胞毒性化合物を請求項１７記載の阻害剤とともに含む、チューブリン重合の阻害用キット。
  9. 少なくとも一つの他の細胞毒性化合物を請求項１８記載の阻害剤とともに含む、チューブリン重合の阻害用キット。
  10. 降圧剤または抗低血圧剤を請求項１５記載の阻害剤とともに含む、チューブリン重合の阻害用キット。
  11. 降圧剤または抗低血圧剤を請求項１６記載の阻害剤とともに含む、チューブリン重合の阻害用キット。
  12. 降圧剤または抗低血圧剤を請求項１７記載の阻害剤とともに含む、チューブリン重合の阻害用キット。
  13. 降圧剤または抗低血圧剤を請求項１８記載の阻害剤とともに含む、チューブリン重合の阻害用キット。
JP2008552645A 2006-02-03 2007-02-02 置換ベンゾフラン、ベンゾチオフェン、ベンゾセレノフェンおよびインドールおよびそれらのチューブリン重合阻害剤としての使用 Active JP5315060B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76533706P 2006-02-03 2006-02-03
US60/765,337 2006-02-03
PCT/AU2007/000101 WO2007087684A1 (en) 2006-02-03 2007-02-02 Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

Publications (3)

Publication Number Publication Date
JP2009531281A JP2009531281A (ja) 2009-09-03
JP2009531281A5 true JP2009531281A5 (ja) 2011-03-10
JP5315060B2 JP5315060B2 (ja) 2013-10-16

Family

ID=38327089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008552645A Active JP5315060B2 (ja) 2006-02-03 2007-02-02 置換ベンゾフラン、ベンゾチオフェン、ベンゾセレノフェンおよびインドールおよびそれらのチューブリン重合阻害剤としての使用

Country Status (12)

Country Link
US (5) US8198466B2 (ja)
EP (2) EP1984333B1 (ja)
JP (1) JP5315060B2 (ja)
AT (1) ATE555091T1 (ja)
AU (1) AU2007211840B2 (ja)
CA (1) CA2640678C (ja)
DK (1) DK1984333T3 (ja)
ES (1) ES2386299T3 (ja)
HK (1) HK1124329A1 (ja)
NZ (1) NZ570014A (ja)
PT (1) PT1984333E (ja)
WO (1) WO2007087684A1 (ja)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416206A (pt) 2003-11-20 2006-12-26 Janssen Pharmaceutica Nv 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-alquenila e 6-fenilalquila como inibidores de polimerase de poli(adp-ribose)
JP4864717B2 (ja) 2003-11-20 2012-02-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼインヒビターとしての７−フェニルアルキル置換２−キノリノンおよび２−キノキサリノン
AU2005259190B2 (en) 2004-06-30 2011-05-12 Janssen Pharmaceutica N.V. Quinazolinedione derivatives as PARP inhibitors
EA012416B1 (ru) 2004-06-30 2009-10-30 Янссен Фармацевтика Н.В. Производные замещенного 2-алкилхиназолинона как ингибиторы parp
ES2563954T3 (es) 2004-06-30 2016-03-16 Janssen Pharmaceutica Nv Derivados de ftalazina como inhibidores de PARP
WO2007087684A1 (en) 2006-02-03 2007-08-09 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
AU2008223793B2 (en) 2007-03-08 2012-08-23 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
ES2448870T3 (es) 2007-10-26 2014-03-17 Janssen Pharmaceutica, N.V. Derivados de quinolina como inhibidores de PARP
RU2490260C2 (ru) 2008-03-27 2013-08-20 Янссен Фармацевтика Нв Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина
ATE513818T1 (de) 2008-03-27 2011-07-15 Janssen Pharmaceutica Nv Chinazolinonderivate als tubulinpolymerisationshemmer
US9006284B2 (en) * 2009-08-27 2015-04-14 Bionomics Limited Combination therapy for treating proliferative diseases
NZ598490A (en) * 2009-08-27 2014-01-31 Bionomics Ltd Treatment of macular degeneration
AU2009240878B2 (en) * 2009-11-27 2016-05-26 Bionomics Limited Combination Therapy for Treating Proliferative Diseases
WO2011063469A1 (en) * 2009-11-27 2011-06-03 Bionomics Limited Tubulin biomarker assay
US20110130367A1 (en) * 2009-11-27 2011-06-02 Bionomics Limited Combination Therapy for Treating Proliferative Diseases
US20130131018A1 (en) 2010-06-04 2013-05-23 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
WO2012006686A1 (en) 2010-07-16 2012-01-19 Bionomics Limited Chemical processes for the manufacture of substituted benzofurans
FR2962731B1 (fr) * 2010-07-19 2012-08-17 Sanofi Aventis Procede de preparation de derives d'amino-benzoyl-benzofurane
WO2012048058A2 (en) * 2010-10-06 2012-04-12 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
AU2011330730B2 (en) 2010-11-18 2016-02-18 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
WO2012077135A2 (en) * 2010-12-09 2012-06-14 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
US9039732B2 (en) 2011-07-11 2015-05-26 Covidien Lp Surgical forceps
CN103906742A (zh) * 2011-09-28 2014-07-02 世宗大学校产学协力团 硒吩稠合芳族化合物和其制备方法
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
CN103058988B (zh) * 2012-12-31 2015-09-02 中国人民大学 苯并噻吩及其衍生物及其制备方法与应用
WO2014175623A1 (ko) * 2013-04-26 2014-10-30 한국생명공학연구원 신규 튜불린 중합 저해제 및 그 합성방법
KR101584731B1 (ko) 2013-04-26 2016-01-12 한국생명공학연구원 신규 튜불린 중합 저해제 및 그 합성방법
CA2944517C (en) * 2014-04-04 2021-03-09 Bionomics Limited Method for treating chronic lymphocytic leukemia
WO2015179893A1 (en) * 2014-05-30 2015-12-03 Bionomics Limited A therapeutic protocol for treating ovarian cancer
AU2015283811A1 (en) * 2014-07-02 2017-02-09 Bionomics Limited Predictive biomarkers
AU2015283795A1 (en) * 2014-07-02 2017-02-09 Bionomics Limited Predicting response to cancer therapy
CN104860908B (zh) * 2015-04-28 2017-03-22 广东颐正达医药科技有限公司 一种合成bnc105的方法
NZ738406A (en) 2015-06-11 2023-04-28 Bionomics Ltd Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof
AU2016366680B2 (en) 2015-12-09 2021-06-24 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP3858835A1 (en) 2016-07-01 2021-08-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
CN107586284B (zh) * 2016-07-06 2021-03-26 中国药科大学 一种2-芳基苯并呋喃类衍生物在制备痛风药物中的用途
WO2018049474A1 (en) 2016-09-16 2018-03-22 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
CN110177554B (zh) 2017-01-06 2023-06-02 G1治疗公司 用于治疗癌症的组合疗法
US10208011B2 (en) 2017-02-10 2019-02-19 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
CA3067873A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of g1t38 and methods of manufacture thereof
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
JP2021120367A (ja) 2020-01-30 2021-08-19 エイムドバイオ株式会社 ベンゾセレノフェン系化合物、これを含む薬学的組成物及び抗体−薬物複合体
KR20240058859A (ko) 2021-08-12 2024-05-03 쿨레온 엘엘씨 환각성 및 비환각성 세로토닌 수용체 작용제 및 이의 제조 및 사용 방법
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE195530T1 (de) 1992-05-20 2000-09-15 Merck & Co Inc 17-ether und thioether von 4-aza-steroiden
CA2135173A1 (en) 1992-05-20 1993-11-25 Bruce E. Witzel Ester derivatives of 4-aza-steroids
EP0915090A1 (en) 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
ATE201398T1 (de) * 1993-11-17 2001-06-15 Kyowa Hakko Kogyo Kk Propenon-derivate
US5728724A (en) * 1995-08-17 1998-03-17 Eli Lilly And Company Benzothiophene compounds
US5886025A (en) 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
EP1058549A4 (en) 1998-12-23 2003-11-12 Bristol Myers Squibb Pharma Co FACTOR Xa OR THROMBIN INHIBITORS
CA2358925C (en) * 1999-02-18 2010-04-20 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
JP4187441B2 (ja) 1999-09-17 2008-11-26 ベイラー・ユニバーシテイ インドール含有およびコンブレタスタチン関連の抗有糸分裂および抗チューブリン重合薬剤
WO2004099139A1 (en) * 2000-09-15 2004-11-18 Baylor University Indole-containing compounds with anti-tubulin and vascular targeting activity
MXPA02005101A (es) 1999-10-18 2003-09-25 Alexipharma Inc Derivados de indol canabimimeticos.
CA2397575A1 (en) 2000-01-13 2001-07-19 Tularik Inc. Antibacterial agents
ATE368046T1 (de) * 2000-03-10 2007-08-15 Univ Baylor Tubulin bindende liganden
US7091240B2 (en) * 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
DE10017947A1 (de) 2000-04-11 2001-10-25 Merck Patent Gmbh Verfahren zur Herstellung benzo-annelierter Heterocyclen
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
FR2813308B1 (fr) 2000-08-23 2005-07-01 Sanofi Synthelabo Aminoalkoxybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation ainsi que les compositions les contenant
AU2002224890B2 (en) 2000-12-05 2007-03-22 F. Hoffmann-La Roche Ag Benzofuran and benzothiophene derivatives as selective COX-2 inhibitors
AUPR283801A0 (en) * 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
GB0106586D0 (en) 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
EP1411052B1 (en) 2001-07-05 2011-10-05 Takeda Pharmaceutical Company Limited Benzo-fused 5-membered hetrocycle compounds,process for preparation of the same, and use thereof
US7528165B2 (en) * 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
JP2006525364A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 置換アミノカルボン酸
US7456214B2 (en) 2004-05-03 2008-11-25 Baylor University Chromene-containing compounds with anti-tubulin and vascular targeting activity
US20050245489A1 (en) * 2004-05-03 2005-11-03 Pinney Kevin G Chromene-containing compounds with anti-tubulin and vascular targeting activity
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
CA2597447C (en) 2005-02-14 2014-03-25 Bionomics Limited Novel tubulin polymerisation inhibitors
WO2007087684A1 (en) 2006-02-03 2007-08-09 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

Similar Documents

Publication Publication Date Title
JP2009531281A5 (ja)
WO2008033798A3 (en) A pyrrolopyrazin as syk-kinase inhibitor
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
WO2008142055A3 (en) Antiviral agents
EA201290397A1 (ru) 1,3,4-оксадиазол-2-карбоксамидное соединение
WO2010017035A3 (en) Inhibitors of iap
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
CL2009000915A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).
JP2009524695A5 (ja)
CL2008001095A1 (es) Uso de compuesto derivados de pirazolopirimidinas, inhibidores de quinasas dependientes de ciclinas para inhibir el crecimiento de un tumor.
GEP20125650B (en) Thiophene or thiazole derivatives and use thereof as pi3k inhibitors
MX2009008506A (es) Derivados del pirazol como inhibidores de 11-b-hsd1.
IL202505A (en) 2-oxo-3-benzyl-benzoxazole-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors, drugs containing them and their uses
TN2010000038A1 (en) Organic compounds
GEP20125704B (en) Plk kinase inhibitors
RS53056B (en) PHARMACEUTICAL PREPARATION CONTAINING (1S) -1,5-ANHYDRO-1- [5- (4-ETHOXYBENZYL) -2-METHOXY-4-METHYLPHENYL] -1-THI-D-GLUCITOL AND METFORMIN AND ITS USE IN THE TREATMENT OF DIABETES
HK1133012A1 (en) Pyrimidinones as casein kinase ii (ck2) modulators
WO2008152014A3 (en) 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
JP2009536652A5 (ja)
IL201064A0 (en) Janus kinase inhibitor compounds, compositions comprising the same and uses thereof